Safety, Feasibility and Therapeutic Activity of Intrapleural Autologous Lymphocyte Conditioned Medium Followed by Systemic Recombinant Interleukin-2 and Interferon-α in a Patient with Malignant Pleural Mesothelioma

1997 ◽  
Vol 12 (3) ◽  
pp. 141-142 ◽  
Author(s):  
Stefan Duensing ◽  
Hinrich Hamm ◽  
Arnold Ganser ◽  
Jens Atzpodien
Keyword(s):  
Conditioned Medium ◽  
Malignant Pleural Mesothelioma ◽  
Interleukin 2 ◽  
Interferon Α ◽  
Pleural Mesothelioma ◽  
Therapeutic Activity ◽  
Autologous Lymphocyte ◽  
Recombinant Interleukin 2

scholarly journals Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact

2009 ◽  
Vol 101 (11) ◽  
pp. 1869-1875 ◽  
Author(s):  
G Alì ◽  
L Boldrini ◽  
M Lucchi ◽  
A Picchi ◽  
M Dell'Omodarme ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Interleukin 2 ◽  
Pleural Mesothelioma ◽  
Prognostic Impact

scholarly journals Therapeutic activity of glycoengineered anti‐ GM 2 antibodies against malignant pleural mesothelioma

2014 ◽  
Vol 106 (1) ◽  
pp. 102-107 ◽  
Author(s):  
Qi Li ◽  
Wei Wang ◽  
Yusuke Machino ◽  
Tadaaki Yamada ◽  
Kenji Kita ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma ◽  
Therapeutic Activity

Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion

Lung Cancer ◽  
2001 ◽  
Vol 31 (2-3) ◽  
pp. 303-310 ◽  
Author(s):  
Bruno Castagneto ◽  
Silvia Zai ◽  
Luciano Mutti ◽  
Antonio Lazzaro ◽  
Ruggero Ridolfi ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma ◽  
Therapeutic Activity

Epirubicin and Gemcitabine as First-Line Treatment in Malignant Pleural Mesothelioma

2005 ◽  
Vol 91 (1) ◽  
pp. 15-18 ◽  
Author(s):  
Luigi Portalone ◽  
Antonio Antilli ◽  
Francesco Nunziati ◽  
Carlo Crispino ◽  
Filippo DeMarinis ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Interleukin 2 ◽  
Tolerability Profile ◽  
Pleural Mesothelioma ◽  
Line Treatment ◽  
Time To Progression ◽  
First Line ◽  
Good Tolerability ◽  
Who Criteria ◽  
First Line Treatment

Malignant pleural mesothelioma represents a rare disease, for which chemotherapy actually remains unsatisfactory. From August 1998 to November 2001, 28 chemo-radio-immunonaive patients were consecutively enrolled in the trial: 22/6 males/females; median age 63 years (range, 45-79); median ECOG PS 1 (range, 0-2). They were treated with epirubicin (100 mg/m2 iv on day 1) plus gemcitabine (1000 mg/m2 iv on days 1 and 8) every 4 weeks for 6 cycles. Patients who responded to chemotherapy (n = 6) were subsequently treated with interleukin-2 (4,500,000 IU) subcutaneously every other day, until progression. A total of 124 epirubicin-gemcitabine cycles were administered (median, 6/patient; range, 2-6). Twenty-six patients were evaluated for toxicity. According to WHO criteria, we observed grade III-IV hematological and gastrointestinal toxicity respectively in 3 patients (11%) and 1 patient (3%). No red cell transfusions were required and no toxic deaths occurred. Two patients (8%) could not be evaluated for response (no therapy performed). According to WHO criteria, the final responses were: partial in 4 patients (14%), stable disease in 19 patients (69%), and progression in 3 patients (10%). In 26 patients, the median survival was 55 weeks (range, 7-222) and median time to progression 30 weeks (range, 4-156). At the time of this writing, no patient is alive. The 1-year survival was 32%, 2-year survival 11%, and 4% at 3 and 4 years. All patients were at stage III, and time to progression was 58 weeks and survival 63.5 weeks, without any toxicity. This multi-center phase II clinical trial showed that epirubicin plus gemcitabine, as a first-line treatment in malignant pleural mesothelioma, has promising activity with a good tolerability profile and symptom palliation. The role of interleukin-2 in maintenance therapy for malignant pleural mesothelioma is encouraging and requires further study.

Sign in / Sign up

Export Citation Format

Share Document